¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"hepar"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(¡­Ò±àõãËúÐ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(?ËÀËÛËàÌ´).
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý<--Ä¡·á>°¨½Ã
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º½ÃÇè.
  • Heparinase
    ÇìÆÄ¸®³×ÀÌÁî
  • heparinase
    ÇìÆÄ¸®³ªÁ¦.
  • heparinase
    ÇìÆÄ¸°ºÐÇØÈ¿¼Ò
  • heparinate
    ÇìÆÄ¸°¿°(¡­ç¤).
  • heparinate
    ÇìÆÄ¸°¿°(?Ëç).
  • heparinemia
    ÇìÆÄ¸°Ç÷(Áõ)(¡­úìñø).
  • heparinemia
    ÇìÆÄ¸°Ç÷(Áõ)(?Ì´Ì¡).
  • heparinization
    ÇìÆÄ¸°È­(?Ì´).
  • heparinized blood
    ÇìÆÄ¸°Ã·°¡Ç÷.
  • heparinoid
    ÇìÆÄ¸®³ëÀ̵å, ÇìÆÄ¸°¾ç(¡­åÆ)ÀÇ.
  • heparinoid
    ÇìÆÄ¸®³ëÀ̵å, ÇìÆÄ¸°¾ç(?Ëâ)ÀÇ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(?ËÀËÛËàÌ´).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(¡­Ò±àõãËúÐ).
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý<--Ä¡·á>°¨½Ã
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º½ÃÇè.
  • heparinase
    ÇìÆÄ¸°ºÐÇØÈ¿¼Ò
  • heparinase
    ÇìÆÄ¸®³ªÁ¦.
  • heparinate
    ÇìÆÄ¸°¿°(?Ëç).
  • heparinate
    ÇìÆÄ¸°¿°(¡­ç¤).
  • heparinemia
    ÇìÆÄ¸°Ç÷(Áõ)(?Ì´Ì¡).
  • heparinemia
    ÇìÆÄ¸°Ç÷(Áõ)(¡­úìñø).
  • heparinization
    ÇìÆÄ¸°È­(?Ì´).
  • heparinized blood
    ÇìÆÄ¸°Ã·°¡Ç÷.
  • heparinoid
    ÇìÆÄ¸®³ëÀ̵å, ÇìÆÄ¸°¾ç(?Ëâ)ÀÇ.
  • heparinoid
    ÇìÆÄ¸®³ëÀ̵å, ÇìÆÄ¸°¾ç(¡­åÆ)ÀÇ.
  • heparinoid substance
    ÇìÆÄ¸°¾ç¹°Áú.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
heparin eliminase <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends.
Chemical name: heparin lyase
Registry number: EC 4.2.2.7
(12 Dec 1998)
heparin lyase <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends.
Chemical name: heparin lyase
Registry number: EC 4.2.2.7
(12 Dec 1998)
heparin unit The quantity of heparin required to keep 1 ml of cat's blood fluid for 24 hr at 0°C; it is equivalent approximately to 0.002 mg of pure heparin.
Synonym: Howell unit.
(05 Mar 2000)
heparin, low-molecular-weight <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
Pharmacological action: anticoagulant, fibrinolytic agent.
(12 Dec 1998)
heparin-glucosamine 3-O-sulfotransferase <enzyme> Reaction: 3'-phosphoadenylylsulfate + heparin-glucosamine = adenosine 3',5'-bisphosphate + heparin glucosamine 3-o-sulfate
Registry number: EC 2.8.2.23
Synonym: glucosaminyl 3-o-sulfotransferase, d-glucosaminyl 3-o-sulfotransferase
(26 Jun 1999)
heparinaemia The presence of demonstrable levels of heparin in the circulating blood.
(05 Mar 2000)
heparinase <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends.
Chemical name: heparin lyase
Registry number: EC 4.2.2.7
(12 Dec 1998)
heparinic acid <drug> Sulphated mucopolysaccharide, found in granules of mast cells, that inhibits the action of thrombin on fibrinogen by potentiating antithrombins, thereby interfering with the blood clotting cascade. Platelet factor IV will neutralise heparin.
(18 Nov 1997)
heparinise To perform therapeutic administration of heparin.
(05 Mar 2000)
heparinoids <chemical> Heparin derivatives. The term has also been used more loosely to include naturally occurring and synthetic highly-sulphated polysaccharides of similar structure. Heparinoid preparations have been used for a wide range of applications including as anticoagulant and anti-inflammatories and they have been claimed to have hypolipidemic properties.
Pharmacological action: anti-inflammatory agents, anticoagulant.
(12 Dec 1998)
heparitin sulfate <chemical> Heparitin, sulfate. A glycosaminoglycan occurring in the liver, aorta, and lung. It has a structure similar to heparin, but there are more n-acetyl groups and fewer o- and n-sulfate groups. It is an accumulation product in several mucopolysaccharidoses.
Chemical name: Heparitin, sulfate
(12 Dec 1998)
heparosan N-sulfate D-glucuronosyl 5-epimerase <enzyme> Converts d-glucuronic acid to l-iduronic at the polymer level during synthesis of heparin
Registry number: EC 5.1.3.17
Synonym: uronosyl c-5 epimerase, d-glucuronyl c-5 epimerase
(26 Jun 1999)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 3 ÆäÀÌÁö: 2
  • Heparin, Low-Molecular-Weight - »õâ Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
    Synonyms : Low Molecular Weight Heparin, Heparin, Low Molecular Weight
  • Heparinoids - »õâ Heparin derivatives. The term has also been used more loosely to include naturally occurring and synthetic highly-sulphated polysaccharides of similar structure. Heparinoid preparations have been used for a wide range of applications including as anticoagulants and anti-inflammatories and they have been claimed to have hypolipidemic properties. (From Martindale, The Extra Pharmacopoeia, 30th, p232)
    Synonyms : Ateroid, Atheroid, Heparinoid
  • Heparitin Sulfate - »õâ A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.
    Synonyms : Sulfate, Heparan, Sulfate, Heparitin
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 5 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 10 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÇìÆÄ·ç½º¿¬Áúݼ¿ - »õâ
º¸·ÉÁ¦¾à
Aminoacetic Acid(Glycine), Ascorbic Acid, Calcium pantothenate, Choline hydrogen tartarate, Cyanocobalamin, Deoxycholic acid, Ferric fumarate, Glutathione(reduced), Inositol, L-arginine, L-aspartic acid, L-cysteine HCl, Lecithin, L-Glutamine, Liver concentrated extract, Liver dried powder, L-methionine, L-ornithine HCl, Nicotinamide, Pyridoxine HCl, Riboflavin, Thiamine nitrate, Thioctic Acid(¥á-lipoic acid), Tocopherol Acetate
ÀϹÝÀǾàǰ | ºñ±Þ¿©
ÇìÆÄ¸®°Õ¿¬Áúݼ¿200mg - »õâ
º¸·ÉÁ¦¾à
A09304201 Timonacic
ÀϹÝÀǾàǰ | ±Þ¿©
³ì½ÊÀÚ»ó¾ÆÇìÆÄ¸°³ªÆ®·ýÁÖ»ç¾× - »õâ
³ì½ÊÀÚ
A35540521 Heparin sodium
Àü¹®ÀǾàǰ | ±Þ¿©
ÇìÆÄµà¿ÀÁ¤ - »õâ
¾¾Æ®¸®
Carduus Marianus extract, L-methionine
ÀϹÝÀǾàǰ | ºñ±Þ¿©
ÇïÇÉÁÖ»ç - »õâ
ºñ¾¾¿ùµåÁ¦¾à
A16250811 Heparin sodium
Àü¹®ÀǾàǰ | »èÁ¦ | ºÐ¾÷¿¹¿ÜÀǾàǰ
ÆÄÀÎÁÖ»ç 25000´ÜÀ§ - »õâ
È޿½º
A29551581 Heparin sodium
Àü¹®ÀǾàǰ | ±Þ¿© | ºÐ¾÷¿¹¿ÜÀǾàǰ
ÇìÆÄ·Îºó¾× - »õâ
µ¿È­¾àǰ°ø¾÷
Betaine, Betaine HCl, Citric acid, L-arginine
ÀϹÝÀǾàǰ | ºñ±Þ¿©
ÆÄÀÎÁÖ»ç 20000´ÜÀ§ - »õâ
È޿½º
A29551571 Heparin sodium
Àü¹®ÀǾàǰ | ±Þ¿© | ºÐ¾÷¿¹¿ÜÀǾàǰ
ÇѸ²ÇìÆÄ¸°³ªÆ®·ýÁÖ5000´ÜÀ§ - »õâ
ÇѸ²Á¦¾à
A37851961 Heparin sodium
Àü¹®ÀǾàǰ | ±Þ¿©
³ì½ÊÀÚÇìÆÄ¸°³ªÆ®·ýÁÖ»ç¾×1000´ÜÀ§ - »õâ
³ì½ÊÀÚ
A35540531 Heparin sodium
Àü¹®ÀǾàǰ | »èÁ¦
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 10 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
heparin lock A small tube connected to a catheter in a vein in the arm for easy access.
Ãâó: www.clevelandclinic.org/heartcenter/pub/glossary/h...
heparin A chemical substance which tends to prevent blood from clotting. Sometimes used in cases of an existing clot in an artery or vein to prevent enlargement of the clot, or the formation of new clots. An anticoagulant.
Ãâó: www.health.qld.gov.au/qldheartkids/glossaryek.asp
heparin A drug that may be added to the solution used to flush eggs out of ovarian follicles during egg retrieval; its purpose is to prevent blood clotting within the fluid that harbors the egg.
Ãâó: www.haveababy.com/learn/glossary.asp
heparin a "blood thinner" given as an injection to prevent blood clots from forming. Sometimes used to treat patients with a history of antiphospholipid syndrome.
Ãâó: www.laborcompanions.com/definitions.htm
heparin An anticoagulant commonly used to prevent the formation of new blood clots (rethrombosis) in the acute myocardial infarction (MI) patient; also used to prevent blood clotting during open-heart surgery.
Ãâó: www.dvt.net/glossary.do
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á